Talus Bioscience, a drug discovery company founded by a world-class team of scientific leaders in proteomics, biochemistry, and machine learning, today announced $11.2M in new venture funding. The Seed+ round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures.

Founded in 2020 by Alex Federation, PhD, and Lindsay Pino, PhD, Talus Bio is a drug discovery and development company focused on therapeutics that target previously undruggable transcription factors. The Seattle-based company's proprietary therapeutics discovery platform, MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors), integrates AI, next-gen proteomics, synthetic chemistry, and computational biology to engineer and interrogate drugs, proteins, and genomics at unprecedented scale. Talus Bio employs a growing team of more than a dozen world-leading experts in proteomics, biochemistry, computational biology, and machine learning.